• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Expiratory central airway collapse associated with poor quality of life

byMilana Bogorodskaya, MDandMichael Milligan
February 3, 2016
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
Recurrent hemoptysis is effectively treated by bronchial artery embolization
Share on FacebookShare on Twitter

1. Expiratory central airway collapse is associated with chronic obstructive pulmonary disease and a poorer quality of life.

2. However, expiratory central airway collapse is not associated with all-cause mortality.

Evidence Rating Level: 3 (Average)

Study Rundown: It is well known that patients with chronic obstructive pulmonary disease (COPD) have a high prevalence of respiratory morbidity, and that chronic smoking is inherently linked to the development and severity of the disease. While expiratory central airway collapse (ECAC) is a known pathophysiological feature of COPD, its clinical significance and prevalence were not clear. Thus, this study utilized chest CT scans to determine which patients experienced ECAC, and correlated this phenomenon with clinical features. Among patients with COPD, 5% were found to have ECAC. Airway collapse was associated with worse respiratory symptoms, worse quality of life, and a higher frequency of COPD exacerbations requiring hospitalization. Furthermore, ECAC was more common in patients who were female, white, had a higher BMI, and had higher stages of COPD.

This study benefited by a large sample number and a broad range of demographic features among the enrolled patient population. Additionally, the inter-reader variability regarding the diagnosis of ECAC on CT scans was low, strengthening the findings of the study. However, this study was not set up to answer the question of how the average clinicians could use this finding to help guide management of these patients, and more research about the clinical utility of this finding is required.

Click to read the study, published today in JAMA

RELATED REPORTS

Artificial intelligence decision support software improved spirometry diagnosis performance in primary care

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

Relevant Reading: Review of adult tracheomalacia and its relationship with chronic obstructive pulmonary disease

In-Depth [cross-sectional study]: This cross-sectional analysis examined inspiratory and expiratory CT images of 8820 current and former smokers aged 45-80 years, to determine the prevalence and clinical significance of ECAC. Patients with known lung disorders other than asthma and COPD were excluded. Primary outcomes included measures of respiratory disease-related health impairment and quality of life, which were assessed through a validated questionnaire. Secondary outcomes included dyspnea, exercise capacity, exacerbation frequency, and all-cause mortality. Collapse of the airways was positive if there was at least a 50% reduction in cross-sectional area of the airway at end-expiration.

Five percent of all participants demonstrated radiographic ECAC, with a higher prevalence in patients with COPD (5.9% vs. 4.3%, 95%CI 0.9% to 2.7%, p < 0.001). Participants with ECAC were more likely to be white, female, have a higher BMI, emphysema, and a higher Gold stage of COPD at the time of the study. These participants also reported a much worse quality of life (SGRQ score 30.9 vs. 26.5, p < 0.001), and had a higher incidence rate ratio of severe COPD exacerbations (IRR 1.39, 95%CI 1.08 to 1.78, p = 0.01). There was no difference in the 6-minute walk test or in all-cause mortality between the two groups.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: copd
Previous Post

Two novel HIV vaccines demonstrate safety and immunogenicity

Next Post

Dupilumab linked to improved symptoms in refractory chronic sinusitis and nasal polyposis

RelatedReports

Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Artificial Intelligence

Artificial intelligence decision support software improved spirometry diagnosis performance in primary care

May 12, 2026
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital
Pharma

GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

August 27, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]

August 14, 2025
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Mepolizumab decreases exacerbations in patients with eosinophilic COPD

May 20, 2025
Next Post
Dupilumab linked to improved symptoms in refractory chronic sinusitis and nasal polyposis

Dupilumab linked to improved symptoms in refractory chronic sinusitis and nasal polyposis

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Moderate seafood consumption associated with decreased risk of Alzheimer pathology

Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]

Antibiotics not linked to improved recovery in acute malnutrition

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Probiotic supplementation is associated with reduced risk of death and necrotizing enterocolitis among preterm infants
  • Artificial intelligence (AI)-triggered rapid response notifications were associated with lower mortality among inpatients
  • Post-traumatic stress disorder is associated with increased risk of mild cognitive impairment and dementia among United States Veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.